A Phase II Study of Bi-weekly XELOX with Bevacizumab for patient with Metastatic Colorectal Cancer as first-line chemotherapy
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: XELIRI plus bevacizumab therapy /Capecitabine;2,000 mg/m2 day1-8(orally, day1 after dinner; day8 after breakfast) /Oxaliplatin 85 mg/m2 day1 /Bevacizumab: 5mg/kg day 1 The treatment is repeated every two weeks until disease progression or severe toxicity Primary outcome(s): progression free survival Study Design: Single arm Non-randomized
创建时间：
2013-03-15
